Cargando…

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review

BACKGROUND: The persistence and effectiveness of systemic therapies for moderate‐to‐severe psoriasis in current clinical practice are poorly characterized. OBJECTIVES: To systematically review observational studies investigating the persistence and effectiveness of acitretin, ciclosporin, fumaric ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Mason, K.J., Williams, S., Yiu, Z.Z.N., McElhone, K., Ashcroft, D.M., Kleyn, C.E., Jabbar‐Lopez, Z.K., Owen, C.M., Reynolds, N.J., Smith, C.H., Wilson, N., Warren, R.B., Griffiths, C.E.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766878/
https://www.ncbi.nlm.nih.gov/pubmed/30628069
http://dx.doi.org/10.1111/bjd.17625
_version_ 1783454788804935680
author Mason, K.J.
Williams, S.
Yiu, Z.Z.N.
McElhone, K.
Ashcroft, D.M.
Kleyn, C.E.
Jabbar‐Lopez, Z.K.
Owen, C.M.
Reynolds, N.J.
Smith, C.H.
Wilson, N.
Warren, R.B.
Griffiths, C.E.M.
author_facet Mason, K.J.
Williams, S.
Yiu, Z.Z.N.
McElhone, K.
Ashcroft, D.M.
Kleyn, C.E.
Jabbar‐Lopez, Z.K.
Owen, C.M.
Reynolds, N.J.
Smith, C.H.
Wilson, N.
Warren, R.B.
Griffiths, C.E.M.
author_sort Mason, K.J.
collection PubMed
description BACKGROUND: The persistence and effectiveness of systemic therapies for moderate‐to‐severe psoriasis in current clinical practice are poorly characterized. OBJECTIVES: To systematically review observational studies investigating the persistence and effectiveness of acitretin, ciclosporin, fumaric acid esters (FAE) and methotrexate, involving at least 100 adult patients with moderate‐to‐severe psoriasis, exposed to therapy for ≥ 3 months. METHODS: MEDLINE, Embase, the Cochrane Library and PubMed were searched from 1 January 2007 to 1 November 2017 for observational studies reporting on persistence (therapy duration or the proportion of patients discontinuing therapy during follow‐up) or effectiveness [improvements in Psoriasis Area and Severity Index (PASI) or Physician's Global Assessment (PGA)]. This review was registered with PROSPERO, number CRD42018099771. RESULTS: Of 411 identified studies, eight involving 4624 patients with psoriasis were included. Variations in the definitions and analyses of persistence and effectiveness outcomes prevented a meta‐analysis from being conducted. One prospective multicentre study reported drug survival probabilities of 23% (ciclosporin), 42% (acitretin) and 50% (methotrexate) at 1 year. Effectiveness outcomes were not reported for either acitretin or ciclosporin. The persistence and effectiveness of FAE and methotrexate were better characterized, but mean discontinuation times ranged from 28 to 50 months for FAE and 7·7 to 22·3 months for methotrexate. At 12 months of follow‐up, three studies reported that 76% (FAE), 53% (methotrexate) and 59% (methotrexate) of patients achieved ≥ 75% reduction in PASI, and one reported that 76% of FAE‐exposed patients achieved a markedly improved or clear PGA. CONCLUSIONS: The comparative persistence and effectiveness of acitretin, ciclosporin, FAE and methotrexate in real‐world clinical practice in the past decade cannot be well described due to the inconsistency of the methods used.
format Online
Article
Text
id pubmed-6766878
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67668782019-10-01 Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review Mason, K.J. Williams, S. Yiu, Z.Z.N. McElhone, K. Ashcroft, D.M. Kleyn, C.E. Jabbar‐Lopez, Z.K. Owen, C.M. Reynolds, N.J. Smith, C.H. Wilson, N. Warren, R.B. Griffiths, C.E.M. Br J Dermatol Evidence‐Based Dermatology BACKGROUND: The persistence and effectiveness of systemic therapies for moderate‐to‐severe psoriasis in current clinical practice are poorly characterized. OBJECTIVES: To systematically review observational studies investigating the persistence and effectiveness of acitretin, ciclosporin, fumaric acid esters (FAE) and methotrexate, involving at least 100 adult patients with moderate‐to‐severe psoriasis, exposed to therapy for ≥ 3 months. METHODS: MEDLINE, Embase, the Cochrane Library and PubMed were searched from 1 January 2007 to 1 November 2017 for observational studies reporting on persistence (therapy duration or the proportion of patients discontinuing therapy during follow‐up) or effectiveness [improvements in Psoriasis Area and Severity Index (PASI) or Physician's Global Assessment (PGA)]. This review was registered with PROSPERO, number CRD42018099771. RESULTS: Of 411 identified studies, eight involving 4624 patients with psoriasis were included. Variations in the definitions and analyses of persistence and effectiveness outcomes prevented a meta‐analysis from being conducted. One prospective multicentre study reported drug survival probabilities of 23% (ciclosporin), 42% (acitretin) and 50% (methotrexate) at 1 year. Effectiveness outcomes were not reported for either acitretin or ciclosporin. The persistence and effectiveness of FAE and methotrexate were better characterized, but mean discontinuation times ranged from 28 to 50 months for FAE and 7·7 to 22·3 months for methotrexate. At 12 months of follow‐up, three studies reported that 76% (FAE), 53% (methotrexate) and 59% (methotrexate) of patients achieved ≥ 75% reduction in PASI, and one reported that 76% of FAE‐exposed patients achieved a markedly improved or clear PGA. CONCLUSIONS: The comparative persistence and effectiveness of acitretin, ciclosporin, FAE and methotrexate in real‐world clinical practice in the past decade cannot be well described due to the inconsistency of the methods used. John Wiley and Sons Inc. 2019-03-27 2019-08 /pmc/articles/PMC6766878/ /pubmed/30628069 http://dx.doi.org/10.1111/bjd.17625 Text en © 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Evidence‐Based Dermatology
Mason, K.J.
Williams, S.
Yiu, Z.Z.N.
McElhone, K.
Ashcroft, D.M.
Kleyn, C.E.
Jabbar‐Lopez, Z.K.
Owen, C.M.
Reynolds, N.J.
Smith, C.H.
Wilson, N.
Warren, R.B.
Griffiths, C.E.M.
Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
title Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
title_full Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
title_fullStr Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
title_full_unstemmed Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
title_short Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
title_sort persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
topic Evidence‐Based Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766878/
https://www.ncbi.nlm.nih.gov/pubmed/30628069
http://dx.doi.org/10.1111/bjd.17625
work_keys_str_mv AT masonkj persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT williamss persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT yiuzzn persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT mcelhonek persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT ashcroftdm persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT kleynce persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT jabbarlopezzk persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT owencm persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT reynoldsnj persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT smithch persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT wilsonn persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT warrenrb persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview
AT griffithscem persistenceandeffectivenessofnonbiologicsystemictherapiesformoderatetoseverepsoriasisinadultsasystematicreview